GlassScriptPhysician profile
Timothy F Lesser
NPI 1053436550
$14,160.00
in general payments reported to CMS, 2019-2025
63 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,457 · 2020: $653 · 2021: $1,972 · 2022: $2,295 · 2023: $2,414 · 2024: $1,711 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,590 · Education: $176 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,590.27 |
| Education | $176.15 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $2,336.06 | 2019-2020 | |
| Sn Holdings, LLC | $1,149.84 | 2021-2023 | |
| Astellas Pharma US INC | $1,049.08 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Abbvie INC. | $1,030.54 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $837.35 | 2019-2025 | Provenge |
| Biotissue Holdings INC. | $672.41 | 2021-2024 | |
| Myriad Genetic Laboratories, INC. | $615.51 | 2022-2025 | Prolaris, Myrisk |
| Sumitomo Pharma America, INC. | $471.34 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $428.48 | 2019-2025 | |
| Janssen Biotech, INC. | $379.24 | 2019-2025 | Erleada |
| Axonics, INC. | $362.25 | 2022-2024 | Axonics |
| Urogen Pharma, INC. | $315.99 | 2022-2025 | Jelmyto |
| Teleflex LLC | $265.50 | 2021-2025 | Urolift, Solesta |
| Procept Biorobotics Corporation | $260.55 | 2019-2025 | Aquabeam System |
| Merck Sharp & Dohme LLC | $258.83 | 2020-2025 | Keytruda, Lynparza, Welireg |
Show all 61 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379,273.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.